<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMLODIPINE BESYLATE - amlodipine besylate tablet </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Amlodipine besylate tabletsThese highlights do not include all the information needed to use Amlodipine Besylate safely and effectively. See full prescribing information for Amlodipine Besylate.Amlodipine Besylate (Amlodipine Besylate) TABLET for ORAL use.Initial U.S. Approval: 2007</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p></p>
<p>
 
</p>
<p></p>
<p>Amlodipine besylate tablets, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with other antihypertensive agents.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Chronic Stable Angina</span></p>
<p>Amlodipine besylate tablets, USP are indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets, USP may be used alone or in combination with other antianginal agents.</p>
<p><span class="Underline">Vasospastic Angina (Prinzmetal’s or <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Variant Angina</span>)</span></p>
<p>Amlodipine besylate tablets, USP are indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets, USP may be used as monotherapy or in combination with other antianginal agents.</p>
<p><span class="Underline">Angiographically Documented CAD</span></p>
<p>In patients with recently documented CAD by angiography and without <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40%, amlodipine besylate tablets, USP are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p></p>
<p>
 
</p>
<p></p>
<p>The usual initial antihypertensive oral dose of amlodipine besylate tablets is 5 mg once daily with a maximum dose of 10 mg once daily.</p>
<p>Small, fragile, or elderly patients, or patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> may be started on 2.5 mg once daily and this dose may be used when adding amlodipine besylate tablets to other antihypertensive therapy.</p>
<p>Adjust dosage according to each patient’s need. In general, titration should proceed over 7 to 14 days so that the physician can fully assess the patient’s response to each dose level. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.</p>
<p>The recommended dose for chronic stable or vasospastic angina is 5 to10 mg, with the lower dose suggested in the elderly and in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Most patients will require 10 mg for adequate effect <span class="Italics">[see</span><span class="Italics"><a href="#bc9997cb-141a-469f-a626-51412307112d"> Adverse Reactions</a></span><span class="Italics"> (</span><span class="Italics"><a href="#b9b5c758-a633-42d2-97c0-f79e686b65bd">6</a></span><span class="Italics">)]</span>.</p>
<p>The recommended dose range for patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is 5 to10 mg once daily. In clinical studies, the majority of patients required 10 mg <span class="Italics">[see </span><span class="Italics"><a href="#b57e5e76-20a3-4365-994e-b989aa9d2f05">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#b084e086-1490-4b29-9999-498f27e81f6b">14.4</a></span><span class="Italics">)]</span>.</p>
<p>
 
</p>
<p></p>
<p>The effective antihypertensive oral dose in pediatric patients ages 6 to 17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients <span class="Italics">[see </span><span class="Italics"><a href="#b66c8faf-3eba-4a06-9237-9307f551317e">Clinical Pharmacology</a></span><span class="Italics"> (</span><span class="Italics"><a href="#bce64b1b-0e0d-4732-ac76-e905897b31e9">12.4</a></span><span class="Italics">), </span><span class="Italics"><a href="#b57e5e76-20a3-4365-994e-b989aa9d2f05">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#bf848923-68a6-4ac3-ab79-cc986c442966">14.1</a></span><span class="Italics">)]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p></p>
<p>2.5 mg, 5 mg, and 10 mg Tablets</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Amlodipine besylate tablets are contraindicated in patients with known sensitivity to amlodipine.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul>
<li> Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. However, because of the gradual onset of action, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> is unlikely. (<a href="#b633393d-6d84-4307-a1e4-85f25558859d">5.1</a>)</li>
<li> Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop after starting or increasing the dose of amlodipine besylate tablets, particularly in patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<a href="#b31c647d-1d8f-4308-94b0-eba0bd7b6722">5.2</a>)</li>
<li> Titrate slowly when administering calcium channel blockers to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#bdee4c07-19f9-4426-be92-ed5a57e09199">5.4</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. Because of the gradual onset of action, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> is unlikely.</p>
<p>
 
</p>
<p></p>
<p>Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop after starting or increasing the dose of amlodipine besylate tablets, particularly in patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
<p>
 
</p>
<p></p>
<p>Amlodipine is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of the dose of beta-blocker.</p>
<p>
 
</p>
<p></p>
<p>Because amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t 1/2) is 56 hours in patients with impaired hepatic function, titrate slowly when administering amlodipine besylate to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p></p>
<p>
 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Amlodipine besylate tablets have been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine besylate tablets were well-tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine besylate tablets were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine besylate tablets (N= 1730) at doses up to</p>
<p>10 mg to placebo (N= 1250), discontinuation of amlodipine besylate tablets due to adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most common side effects are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The incidence (%) of side effects that occurred in a dose related manner are as follows:</p>
<table width="590">
<caption><span></span></caption>
<tbody class="Headless">
<tr class="First">
<td><span>Adverse Event</span></td>
<td>2.5 mg</td>
<td>5.0 mg</td>
<td>10.0 mg</td>
<td>Placebo</td>
</tr>
<tr>
<td>N=275</td>
<td>N=296</td>
<td>N=268</td>
<td>N=520</td>
</tr>
<tr><td></td></tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td>1.8</td>
<td>3.0</td>
<td>10.8</td>
<td>0.6</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td>1.1</td>
<td>3.4</td>
<td>3.4</td>
<td>1.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> </td>
<td>0.7</td>
<td>1.4</td>
<td>2.6</td>
<td>0.0</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></td>
<td>0.7</td>
<td>1.4</td>
<td>4.5</td>
<td>0.6</td>
</tr>
</tbody>
</table>
<p>Other adverse experiences that were not clearly dose related but were reported with an incidence greater than 1.0% in placebo-controlled clinical trials include the following:</p>
<table width="480">
<caption><span> Placebo-Controlled Studies</span></caption>
<tbody class="Headless">
<tr class="First">
<td></td>
<td> Amlodipine (%)</td>
<td> Placebo (%)</td>
</tr>
<tr>
<td></td>
<td> (N=1730)</td>
<td> (N=1250)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td>7.3</td>
<td>7.8</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td>4.5</td>
<td>2.8</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td>2.9</td>
<td>1.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </td>
<td>1.6</td>
<td>0.3</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td>1.4</td>
<td>0.6</td>
</tr>
</tbody>
</table>
<p>For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table:</p>
<table width="565"><tbody class="Headless">
<tr class="First">
<td><span>Adverse Event</span></td>
<td>Amlodipine</td>
<td>Placebo</td>
</tr>
<tr>
<td>Male = %</td>
<td>Female = %</td>
<td>Male = %</td>
<td>Female = %</td>
</tr>
<tr>
<td>(N=1218)</td>
<td>(N=215)</td>
<td>(N=914)</td>
<td>(N=336)</td>
</tr>
<tr><td></td></tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td>5.6</td>
<td>14.6</td>
<td>1.4</td>
<td>5.1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td>1.5</td>
<td>4.5</td>
<td>0.3</td>
<td>0.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></td>
<td>1.4</td>
<td>3.3</td>
<td>0.9</td>
<td>0.9</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td>1.3</td>
<td>1.6</td>
<td>0.8</td>
<td>0.3</td>
</tr>
</tbody></table>
<p>The following events occurred in &lt;1% but &gt;0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Bold">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="Sup">1</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>,<span class="Sup">1</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p><span class="Bold">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="Sup">1</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male<span class="Sup">1</span> and female), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>.</p>
<p><span class="Bold">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="Sup">1</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="Sup">1</span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="Sup">1</span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Bold">Urinary System:</span> micturition frequency, micturition disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p><span class="Bold">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>.</p>
<p><span class="Bold">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.</p>
<p><span class="Bold">Hemopoietic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Sup">1</span>These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.</p>
<p>The following events occurred in &lt;0.1% of patients: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, pulse irregularity, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, skin dryness, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, abnormal visual accommodation, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>.</p>
<p>Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and angina.</p>
<p>Amlodipine therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, uric acid, blood urea nitrogen, or creatinine.</p>
<p>In the CAMELOT and PREVENT studies <span class="Italics">[see </span><span class="Italics"><a href="#b57e5e76-20a3-4365-994e-b989aa9d2f05">Clinical Studies</a></span><span class="Italics"> (</span><span class="Italics"><a href="#b084e086-1490-4b29-9999-498f27e81f6b">14.4</a></span><span class="Italics">)]</span>, the adverse event profile was similar to that reported  previously (see above), with the most common adverse event being <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p>
 
</p>
<p></p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following postmarketing event has been reported infrequently where a causal relationship is uncertain: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. In postmarketing experience, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.</p>
<p>Amlodipine besylate tablets have been used safely in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, well-compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4042056" conceptname="Lipids abnormal">abnormal lipid profiles</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<ul><li> If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin. (<a href="#bf583235-5090-44a3-b2b7-a73a30bb521d">7.7</a>)</li></ul>
<p>
 
</p>
<p></p>
<p><span class="Italics">In vitro</span> data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate tablets had no significant effect on the pharmacokinetics of amlodipine.</p>
<p>
 
</p>
<p></p>
<p>A single 100 mg dose of sildenafil in subjects with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in 77 % increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patient on amlodipine to 20 mg daily</p>
<p>
 
</p>
<p></p>
<p>Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.</p>
<p>
 
</p>
<p></p>
<p>Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of amlodipine with warfarin did not change the warfarin <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> when amlodipine is co-administered with CYP3A4 inhibitors.</p>
<p>
 
</p>
<p></p>
<p>No information is available on the quantitative effects of CYP3A4 inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A4 inducers.</p>
<p>
 
</p>
<p></p>
<p>None known.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<ul>
<li> Pregnancy: Use only if the potential benefit justifies the potential risk. (<a href="#b445be20-31ae-401c-9162-541585e8312f">8.1</a>)</li>
<li> Nursing: Discontinue when administering amlodipine besylate tablets. (<a href="#b9441b6e-9ca7-4b94-abff-a86d8c1eccb2">8.3</a>)</li>
<li> Pediatric: Effect on patients less than 6 years old is not known. (<a href="#b564aa05-4b27-4267-a748-a0ae548e5682">8.4</a>)</li>
<li> Geriatric: Start dosing at the low end of the dose range, due to the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. (<a href="#b586d415-9377-4ba5-bb85-95456e647528">8.5</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (respectively, 8 times<span class="Sup">2</span> and 23 times<span class="Sup">2</span> the maximum recommended human dose of 10 mg on a mg/m<span class="Sup">2</span> basis) during their respective periods of major organogenesis. However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.</p>
<p><span class="Sup">2</span> Based on patient weight of 50 kg.</p>
<p>
 
</p>
<p></p>
<p>It is not known whether amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while amlodipine is administered.</p>
<p>
 
</p>
<p></p>
<p>Effect of amlodipine on blood pressure in patients less than 6 years of age is not known.</p>
<p>
 
</p>
<p></p>
<p>Clinical studies of amlodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40 to 60%, and a lower initial dose may be required <span class="Italics">[see </span><span class="Italics"><a href="#b7129856-2a16-4510-96b9-beef96de2547">Dosage and Administration</a></span><span class="Italics"> (</span><span class="Italics"><a href="#bc8581cf-0645-403a-ae25-cfbbb00e82e2">2.1</a></span><span class="Italics">)]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Overdosage might be expected to cause excessive peripheral vasodilation with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and possibly a <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>. In humans, experience with intentional overdosage of amlodipine is limited.</p>
<p>Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>If massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, provide cardiovascular support including elevation of the extremities and the judicious administration of fluids. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Amlodipine besylate, USP is the besylate salt of amlodipine, a long-acting calcium channel blocker.</p>
<p>Amlodipine besylate, USP is chemically described as 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">25</span>CIN<span class="Sub">2</span>O<span class="Sub">5</span> • C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S, and its structural formula is:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82507337-cd5e-48f4-891b-dda1512bcb9f&amp;name=MM1.jpg"></p>
<p>Amlodipine besylate, USP is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. Amlodipine besylate tablets, USP are formulated as white tablets equivalent to 2.5 mg, 5 mg, and 10 mg of amlodipine for oral administration. In addition to the active ingredient, amlodipine besylate, USP each tablet contains the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected <span class="Italics">in vitro</span> but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa= 8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure.</p>
<p>The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following:</p>
<p>Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.</p>
<p>Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels <span class="Italics">in vitro</span>. This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal’s or variant) angina.</p>
<p>
 
</p>
<p></p>
<p>Hemodynamics: Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine besylate tablets produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.</p>
<p>With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine besylate tablets is also correlated with the height of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 105 to 114 mmHg) had about a 50% greater response than patients with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90 to 104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/-2 mmHg).</p>
<p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine besylate tablets resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine besylate tablets have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine besylate tablets have not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing significant negative inotropic effects.</p>
<p>Electrophysiologic Effects: Amlodipine besylate tablets do not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine besylate tablets and concomitant beta-blockers. In clinical studies in which amlodipine besylate tablets were administered in combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects on electrocardiographic parameters was observed. In clinical trials with angina patients alone, amlodipine besylate tablet therapy did not alter electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>.</p>
<p>
 
</p>
<p></p>
<p>After oral administration of therapeutic doses of amlodipine besylate tablets, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of amlodipine besylate tablets is not altered by the presence of food.</p>
<p>Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. <span class="Italics">Ex vivo</span> studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours. Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing.</p>
<p>The pharmacokinetics of amlodipine are not significantly influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore receive the usual initial dose.</p>
<p>Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40 to 60%, and a lower initial dose may be required. A similar increase in AUC was observed in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p>
 
</p>
<p></p>
<p>Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine besylate tablets between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p>Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5 mg, 1.25 mg, or 2.5 amlodipine mg/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on a mg/m<span class="Sup">2</span> basis, similar to the maximum recommended human dose of 10 mg amlodipine/day. <span class="Sup">3</span> For the rat, the highest dose was, on a mg/m<span class="Sup">2</span> basis, about twice the maximum recommended human dose. <span class="Sup">3</span></p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug related effects at either the gene or chromosome level.</p>
<p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses up to 10 mg amlodipine/kg/day (8 times the maximum recommended human dose<span class="Sup">3</span> of 10 mg/day on a mg/m<span class="Sup">2</span> basis).</p>
<p><span class="Sup">3</span>  Based on patient weight of 50 kg</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p><span class="Bold">Adult Patients </span></p>
<p>The antihypertensive efficacy of amlodipine besylate tablets has been demonstrated in a total of 15 double-blind, placebo-controlled, randomized studies involving 800 patients on amlodipine besylate tablets and 538 on placebo. Once daily administration produced statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours post dose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Maintenance of the blood pressure effect over the 24-hour dosing interval was observed, with little difference in peak and trough effect. Tolerance was not demonstrated in patients studied for up to 1 year. The 3 parallel, fixed dose, dose response studies showed that the reduction in supine and standing blood pressures was dose-related within the recommended dosing range. Effects on diastolic pressure were similar in young and older patients. The effect on systolic pressure was greater in older patients, perhaps because of greater baseline systolic pressure. Effects were similar in black patients and in white patients.</p>
<p><span class="Bold">Pediatric Patients </span></p>
<p>Two hundred sixty-eight hypertensive patients aged 6 to 17 years were randomized first to amlodipine besylate tablets 2.5 or 5 mg once daily for 4 weeks and then randomized again to the same dose or to placebo for another 4 weeks. Patients receiving 2.5 mg or 5 mg at the end of 8 weeks had significantly lower systolic blood pressure than those secondarily randomized to placebo. The magnitude of the treatment effect is difficult to interpret, but it is probably less than 5 mmHg systolic on the 5 mg dose and 3.3 mmHg systolic on the 2.5 mg dose. Adverse events were similar to those seen in adults.</p>
<p>
 
</p>
<p></p>
<p>The effectiveness of 5 to 10 mg/day of amlodipine besylate tablets in exercise-induced angina has been evaluated in 8 placebo-controlled, double-blind clinical trials of up to 6 weeks duration involving 1038 patients (684 amlodipine besylate tablets, 354 placebo) with chronic stable angina. In 5 of the 8 studies, significant increases in exercise time (bicycle or treadmill) were seen with the 10 mg dose. Increases in symptom-limited exercise time averaged 12.8% (63 sec) for amlodipine besylate tablets 10 mg, and averaged 7.9% (38 sec) for amlodipine besylate tablets 5 mg. amlodipine besylate tablets 10 mg also increased time to 1 mm ST segment deviation in several studies and decreased <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attack</span> rate. The sustained efficacy of amlodipine besylate tablets in angina patients has been demonstrated over long-term dosing. In patients with angina, there were no clinically significant reductions in blood pressures (4/1 mmHg) or changes in heart rate (+0.3 bpm).</p>
<p>
 
</p>
<p></p>
<p>In a double-blind, placebo-controlled clinical trial of 4 weeks duration in 50 patients, amlodipine besylate tablet therapy decreased attacks by approximately 4/week compared with a placebo decrease of approximately 1/week (p&lt;0.01). Two of 23 amlodipine besylate tablet and 7 of 27 placebo patients discontinued from the study due to lack of clinical improvement.</p>
<p>
 
</p>
<p></p>
<p>In PREVENT, 825 patients with angiographically documented <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> were randomized to amlodipine besylate tablets (5 to 10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p>
<p>CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> and without <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine besylate tablets (5 to 10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, coronary revascularization, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine besylate tablet and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540 to 0.884, p = 0.003). The primary endpoint is summarized in <span class="Bold"><a href="#b022f6ea-8283-4a8e-a169-5a16c6c21c72">Figure 1</a></span> below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see <span class="Bold"><a href="#b054c38a-a479-423e-808a-6cd487dbe201">Table 1</a></span>). Effects in various subgroups are shown in <span class="Bold"><a href="#bafb51b1-8be0-42b6-9dfc-fb36562e8122">Figure 2</a></span>.</p>
<p>In an angiographic substudy (n= 274) conducted within CAMELOT, there was no significant difference between amlodipine and placebo on the change of atheroma volume in the coronary artery as assessed by intravascular ultrasound.</p>
<p><a name="b022f6ea-8283-4a8e-a169-5a16c6c21c72"></a>[IC]<span class="Bold"> Figure 1 - Kaplan-Meier Analysis of Composite Clinical Outcomes for amlodipine versus Placebo</span>[/IC]</p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82507337-cd5e-48f4-891b-dda1512bcb9f&amp;name=MM2.jpg"></p>
<p> Figure 2 – Effects on Primary Endpoint of amlodipine versus Placebo across Sub-Groups</p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82507337-cd5e-48f4-891b-dda1512bcb9f&amp;name=MM3.jpg"></p>
<p>Table 1 below summarizes the significant composite endpoint and clinical outcomes from the composites of the primary endpoint. The other components of the primary endpoint including cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> did not demonstrate a significant difference between amlodipine and placebo.</p>
<a name="b054c38a-a479-423e-808a-6cd487dbe201"></a><table width="568">
<caption><span> Table 1.</span></caption>
<tbody class="Headless">
<tr class="First"><td><span class="Bold">Incidence of Significant Clinical Outcomes for CAMELOT</span></td></tr>
<tr>
<td><span class="Bold">Clinical Outcomes</span></td>
<td><span class="Bold">NORVASC</span></td>
<td><span class="Bold">Placebo</span></td>
<td><span class="Bold">Risk Reduction</span></td>
</tr>
<tr>
<td><span class="Bold">N (%)</span></td>
<td><span class="Bold">(N=663)</span></td>
<td><span class="Bold">(N=655)</span></td>
<td><span class="Bold">(p-value)</span></td>
</tr>
<tr>
<td><span class="Bold">Composite CV </span></td>
<td><span class="Bold">110</span></td>
<td><span class="Bold">151</span></td>
<td><span class="Bold">31%</span></td>
</tr>
<tr>
<td><span class="Bold">Endpoint</span></td>
<td><span class="Bold">(16.6)</span></td>
<td><span class="Bold">(23.1)</span></td>
<td><span class="Bold">(0.003)</span></td>
</tr>
<tr><td></td></tr>
<tr>
<td>Hospitalization for Angina<span class="Sup">*</span>
</td>
<td>51</td>
<td>84</td>
<td>42%</td>
</tr>
<tr>
<td></td>
<td>(7.7)</td>
<td>(12.8)</td>
<td>(0.002)</td>
</tr>
<tr><td></td></tr>
<tr>
<td>Coronary Revascularization<span class="Sup">*</span>
</td>
<td>78</td>
<td>103</td>
<td>27%</td>
</tr>
<tr>
<td></td>
<td>(11.8)</td>
<td>(15.7)</td>
<td>(0.033)</td>
</tr>
<tr class="Last"><td></td></tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>Amlodipine besylate tablets have been compared to placebo in four 8 to 12 week studies of patients with NYHA Class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 patients. In these studies, there was no evidence of worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on measures of exercise tolerance, NYHA classification, symptoms, or left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span>. In a long-term (follow-up at least 6 months, mean 13.8 months) placebo-controlled mortality/morbidity study of amlodipine besylate tablets 5-10 mg in 1153 patients with NYHA Classes III (n=931) or IV (n=222) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable doses of diuretics, digoxin, and ACE inhibitors, amlodipine had no effect on the primary endpoint of the study which was the combined endpoint of all-cause mortality and cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), or on NYHA classification, or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Total combined all-cause mortality and cardiac morbidity events were 222/571 (39%) for patients on amlodipine besylate tablets and 246/583 (42%) for patients on placebo; the cardiac morbid events represented about 25% of the endpoints in the study.</p>
<p>Another study (PRAISE-2) randomized patients with NYHA Class III (80%) or IV (20%) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> without clinical symptoms or objective evidence of underlying ischemic disease, on stable doses of ACE inhibitors (99%), digitalis (99%), and diuretics (99%), to placebo (n= 827) or amlodipine besylate tablets (n= 827) and followed them for a mean of 33 months. There was no statistically significant difference between amlodipine besylate tablets and placebo in the primary endpoint of all-cause mortality (95% confidence limits from 8% reduction to 29% increase on amlodipine). With amlodipine besylate tablets there were more reports of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Amlodipine besylate-2.5 mg Tablets (amlodipine besylate, USP equivalent to 2.5 mg of amlodipine per tablet) are supplied as white, round, flat-faced, beveled edged tablets debossed with IG on one side and 237 on the other and supplied as follows:</p>
<p>NDC 31722-237-90 Bottle of 90<br>NDC 31722-237-10 Bottle of 1000</p>
<p>
 
</p>
<p></p>
<p>Amlodipine besylate-5 mg Tablets (amlodipine besylate, USP equivalent to 5 mg of amlodipine per tablet) are supplied as white, round, flat-faced, beveled edged tablets debossed with IG on one side and 238 on the other and supplied as follows:</p>
<p>NDC 31722-238-90 Bottle of 90<br>NDC 31722-238-10 Bottle of 1000</p>
<p>
 
</p>
<p></p>
<p>Amlodipine besylate-10 mg Tablets (amlodipine besylate, USP equivalent to 10 mg of amlodipine per tablet) are supplied as white, round, flat-faced, beveled edged tablets debossed with IG on one side and 239 on the other and supplied as follows:</p>
<p>NDC 31722-239-90 Bottle of 90<br>NDC 31722-239-10 Bottle of 1000</p>
<p>
 
</p>
<p></p>
<p>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].</p>
<p>Manufactured by:<br>InvaGen Pharmaceuticals, Inc.<br>Hauppauge, NY 11788</p>
<p>Manufactured for:<br>Camber Pharmaceuticals, Inc.<br>Piscataway, NJ 08854</p>
<p>Rev: 07/12</p>
<p><span class="Bold">SUMMARY OF INFORMATION ABOUT</span><span class="Bold"><br></span><span class="Bold">AMLODIPINE BESYLATE TABLETS, USP</span></p>
<p>Read this information carefully before you start taking amlodipine besylate tablets and each time you refill your prescription. There may be new information. This information does not replace talking with your doctor. If you have any questions about amlodipine besylate tablets, ask your doctor. Your doctor will know if amlodipine besylate tablets are right for you.</p>
<p><span class="Bold">What are amlodipine besylate tablets? </span></p>
<p>Amlodipine besylate tablets are a type of medicine known as a calcium channel blocker (CCB). It is used to treat high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) and a type of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> called angina. It can be used by itself or with other medicines to treat these conditions.</p>
<p><span class="Bold">High Blood Pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) </span></p>
<p>High blood pressure comes from blood pushing too hard against your blood vessels. Amlodipine besylate tablets relaxes your blood vessels, which lets your blood flow more easily and helps lower your blood pressure. Drugs that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p>
<p><span class="Bold">Angina </span></p>
<p>Angina is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that keeps coming back when part of your heart does not get enough blood. Angina feels like a pressing or squeezing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, usually in your chest under the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaws, or back. Amlodipine besylate tablets can relieve this <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Bold">Who should not use amlodipine besylate tablets? </span></p>
<p>Do not use amlodipine besylate tablets if you are allergic to amlodipine (the active ingredient in amlodipine), or to the inactive ingredients. Your doctor or pharmacist can give you a list of these ingredients.</p>
<p><span class="Bold">What should I tell my doctor before taking amlodipine besylate tablets? </span></p>
<p>Tell your doctor about any prescription and non-prescription medicines you are taking, including natural or herbal remedies. Tell your doctor if you:</p>
<p>?ever had heart disease?ever had liver problems?are pregnant, or plan to become pregnant. Your doctor will decide if amlodipine besylate tablets are the best treatment for you.?are breast-feeding. Do not breast-feed while taking amlodipine besylate tablets.  You can stop breast-feeding or take a different medicine.</p>
<p><span class="Bold">How should I take amlodipine besylate tablets? </span></p>
<p>?Take amlodipine once a day, with or without food.?It may be easier to take your dose if you do it at the same time every day, such as with breakfast or dinner, or at bedtime. Do not take more than one dose of amlodipine besylate tablets at a time.?If you miss a dose, take it as soon as you remember. Do not take amlodipine besylate tablets if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time.?Other medicines: You can use nitroglycerin and amlodipine besylate tablets together. If you take nitroglycerin for angina, don’t stop taking it while you are taking amlodipine besylate tablets.?While you are taking amlodipine besylate tablets, do not stop taking your other prescription medicines, including any other blood pressure medicines, without talking to your doctor.?If you took too many amlodipine besylate tablets, call your doctor or Poison Control Center, or go to the nearest hospital emergency room right away.</p>
<p><span class="Bold">What should I avoid while taking amlodipine besylate tablets? </span></p>
<p>?</p>
<p><span class="Bold">Do not</span></p>
<p> breast-feed. It is not known if amlodipine will pass through your milk.?</p>
<p><span class="Bold">Do not</span></p>
<p> start any new prescription or non-prescription medicines or supplements, unless you check with your doctor first.</p>
<p><span class="Bold">What are the possible side effects of amlodipine besylate tablets? </span></p>
<p>Amlodipine besylate tablets may cause the following side effects. Most side effects are mild or moderate:</p>
<p>?headache?<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your legs or ankles?<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, extreme sleepiness?<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, nausea?dizziness?<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (hot or warm feeling in your face)?<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (irregular heartbeat)?heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> (very fast heartbeat)</p>
<p>It is rare, but when you first start taking amlodipine besylate tablets or increase your dose, you may have a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or your angina may get worse. If that happens, call your doctor right away or go directly to a hospital emergency room.</p>
<p>Tell your doctor if you are concerned about any side effects you experience. These are not all the possible side effects of amlodipine. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">How do I store amlodipine besylate tablets? </span></p>
<p>Keep amlodipine besylate tablets away from children. Store amlodipine besylate tablets at room temperature (store between 20° to 25°C (68° to 77°F). Keep amlodipine besylate tablets out of the light. Do not store in the bathroom. Keep amlodipine besylate tablets in a dry place.</p>
<p><span class="Bold">General advice about amlodipine besylate tablets </span></p>
<p>Sometimes, doctors will prescribe a medicine for a condition that is not written in the patient information leaflets. Only use amlodipine besylate tablets the way your doctor told you to. Do not give amlodipine besylate tablets to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>You can ask your pharmacist or doctor for information about amlodipine besylate tablets, or you can visit Camber Pharmaceuticals website at <span class="Bold">www.camberpharma.com</span> or call 1-866-495-8330.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.</span></p>
<p>Manufactured by:<br>InvaGen Pharmaceuticals, Inc.<br>Hauppauge, NY 11788</p>
<p>Manufactured for:<br>Camber Pharmaceuticals, Inc.<br>Piscataway, NJ 08854<br>Rev: 07/12<br>Barcode: 239-07-2012</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Amlodipine Besylate </p>
<p><br></p>
<p>GENERIC: Amlodipine Besylate</p>
<p><br></p>
<p>DOSAGE: TABLET</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 61786-071-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>AMLODIPINE BESYLATE 5mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</li>
<li>SODIUM STARCH GLYCOLATE TYPE A POTATO</li>
<li>CELLULOSE, MICROCRYSTALLINE</li>
<li>MAGNESIUM STEARATE</li>
</ul>
<p><br></p>
<p>COLOR: white</p>
<p><br></p>
<p>SHAPE: ROUND</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 6 mm</p>
<p><br></p>
<p>IMPRINT: 238;IG</p>
<p><br></p>
<p>PACKAGING: 30  in 1 BOTTLE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82507337-cd5e-48f4-891b-dda1512bcb9f&amp;name=MM4.jpg"></p>
<p><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82507337-cd5e-48f4-891b-dda1512bcb9f&amp;name=MM5.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE 		
					</strong><br><span class="contentTableReg">amlodipine besylate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61786-071(NDC:31722-238)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">238;IG</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61786-071-02</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077995</td>
<td class="formItem">10/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>06992466-5a5b-4c61-9498-237bb883fd1c</div>
<div>Set id: 82507337-cd5e-48f4-891b-dda1512bcb9f</div>
<div>Version: 1</div>
<div>Effective Time: 20141020</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
